Cardiovascular risk of Janus kinase inhibitors compared with biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis without underlying cardiovascular diseases: a nationwide cohort study

Objectives: Despite the ethnic differences in cardiovascular (CV) risks and recent increase in the prescription of Janus kinase (JAK) inhibitors, limited evidence is available for their CV outcomes in Asian patients with rheumatoid arthritis (RA). We aimed to compare the major adverse CV events (MAC...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yun-Kyoung, Lee, Gaeun, Hwang, Jinseub, Kim, Ji-Won, Kwon, Jin-Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642260/
https://www.ncbi.nlm.nih.gov/pubmed/37964868
http://dx.doi.org/10.3389/fphar.2023.1165711

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642260/
https://www.ncbi.nlm.nih.gov/pubmed/37964868
http://dx.doi.org/10.3389/fphar.2023.1165711

Ejemplares similares